

Intestinal Microflora Vs Protozoan Parasites: From Interaction to Competition

ABSTRACT

Aims: To reveal the interaction between intestinal microflora and the protozoan parasite organisms and how it affect their host's performance.

Discussion: The vertebrate gastro-intestinal system contain wide array of diverse but dynamic bacterial microbiota population that has ubiquitous consequences on its host's well-being including physiology, nutrition, metabolism, and immunity, locally and systematically. Naturally, these bacteria share their milleu with a more or less similar population of parasitic eukaryotes (e.g., protozoan, helminths, and fungi). Both eukaryotes parasites in combination with the prokaryotic microorganisms as inhabitant normal microflora can dynamically shift the bio-physics and immune milleu of the intestine (locally) or even can affect its host as a whole (systematically), creating abundant chances for them to interact to each other; where ideally, both side is in equilibrium state. Beside their function, intestinal normal (commensal) microflora mainly contribute in several activities that control parasite survival and determines the outcome of several, if not many, parasite-base disease. Normal microflora actively limiting the pathogenicity of many parasites. The steadiness among the number and composition of normal microflora and its host seems vital to the host's well-being perpetuation. But unfortunately, this interaction can further shifted into competition that can leads to the dominance of one party in number and probably also strength. Those spectrum of interactions may critically modify infection outcomes (active or dormant/carrier) and in turn affect the overall host condition. Active protozoan invasion may modify interaction between hosts and their normal resident microflora, either supporting or preventing against the condition of dysbiosis and inflammatory disease. Conversely, the microbiota controls parasite's settlement, multiplication, and even virulence; the properties that can modulate the interaction along the parasitism-mutualism sphere.

Conclusion: Intestinal microflora composition control the pathogenesis of the protozoan infections.

Keywords: microflora, symbiont, parasitism, fungi, helminths, protozoans, probiotics, domination

1. INTRODUCTION

Microorganisms interacts with each other and can be physically associated with another organisms in a variety of ways [1]. The microorganism–host or microorganism–microorganism interactions are central for the establishment of non-inhabitant organisms in various condition of environments [1,2]. Synergism between these organisms involve in all important life related ecological aspects, including bio-physico-chemical swapping, metabolite swapping-conversion-signaling, the process of chemotaxis and also genetic

swapping ensuing in genotype selection [3]. furthermore, the accomplishment of certain organism in a specific local milieu based on the diversity of the species, since high functional redundancy in the microbial community elevates the competitive ability of the community, lowering the possibility of an outsider-invader to exhibit themselves in certain milieu [4]. Although there may be internal changes on the host's side that facilitating competition [5].

Competition is a biological interaction between two or more organisms of the same or different species where the species compete with each other for different resources [6,7]. Most of the competitive interaction occurs for nutrition fulfillment [8]. This ultimate need of food sources usually occur in a limited supply when compared to demand, and this is the very basic reason of competition, host-microorganism or microorganism-microorganism and even host-microorganism-parasite [3,5].

The aim of this literature study is to review the spectrum of interaction between intestinal microflora vs parasitic organism and how this relation interfere with their host well being.

2. THE HUMAN INTESTINAL MICROBIOTA

Gastro-intestinal system of human constitutes a unique and sophisticated biosphere. It consist of large number of 'good' microorganism community that related with essential functions of the well being of their host's body [9]. The species abundance varies greatly between individuals, with each person containing an eccentric and dynamic cluster of microorganisms, which may fluctuate steadily [7-9].

Genetic factors, to some extent, facilitate the development of intestinal microbiota, although on the host's body [10,11]. Nowadays, the human body along with its 'passenger' normal microflora has been called a "superorganism" due to the reason there is widespread link between nutritional-metabolic-physiological activities that involving the synergism of various organs/systems [12,13].

In the context of intestine, the existence of numerous normal microflora reinforce their host with several crucial roles, namely in (1) First line of defense against microbial pathogens [2], (2) Facilitates digestion process [1,6], (3) Regulating host fat storage [9], (4) Contributes to maturation of the immune system [7], (5) Stimulating intestinal epithelium renewal [1,9], (6) vitamin synthesis-metabolism [15,16], (7) xenobiotics and drug metabolism [17,18].

The equilibrium state among the normal microflora and their human host is important in maintaining health and homeostasis, and the derangement of normal microflora, in number and or configuration, has been purported to be elaborated in a wide array of ailment formation [2,6,7,12,13,19]. Moreover, the commensal microflora devotes to the "barrier properties" of the gut epithelial, which lining the intestinal luminal surface and contributes primarily to protect their host, representing a real hindrance to pathogens assault [4,6,10].

Within this sophisticated framework, due to poor practice of hygiene, intestinal parasites from outer world sometime manage to enter and then reach its predilection site [1]. These parasites interrelate with the existing normal microflora population [3,5,6]. Those meeting can modify the equilibrium condition between normal gut microflora and their host. Each of them have the capability to metabolizes and modifies nutritive compound, interactively.

Resident normal microflora and its by-products may directly affect the survival and the fitness of many parasitic organism and, accordingly, with the clinical progression of many

type of parasitic illness [20]. At the same time, intestinal parasites, e.g., protozoans and helminths, also persistently produce micro-substance that may alter or modify local milieu where they exist; this may shift intestinal microflora, in number and or in compositions. Furthermore, this relation of parasite-normal microflora actually can facilitate the pathogenesis of severe disease in COVID-19; and this phenomenon has been linked to the condition of immune hyperactivation [21].

To some extent, native microflora of the intestine also able to extract and produce energy from nutritive metabolism that can be used for the benefit of the host; even though it is also beneficial to parasitic organisms, whenever they exist [22,23]. Beside vitamin biosynthesis, they involve in their host's macronutrient metabolism by the gut microbiome that affects their host's health by way producing metabolites that interfere with short-chain fatty acids and alcohols (mainly yielded from monosaccharides); ammonia, branched-chain fatty acids, amines, sulfur compounds, phenols, and indoles (derived from amino acids); glycerol and choline derivatives (obtained from the breakdown of lipids); and tertiary cycling of carbon dioxide and hydrogen. [16, 22]. Furthermore, local normal microbiota also involve in tryptophan (Trp) metabolism in the intestine, where the three main Trp metabolism pathways leading to the production of serotonin (5-hydroxytryptamine), kynurenine (Kyn), and indole derivatives are under the control of the inhabitant microbiota, directly or indirectly [23]. It is therefore relevant to consider the intestinal specific milieu as an unique and controlled ecological community where dynamic and persistent bio-chemical interlinkages exist at copious organizational stages affecting the host - normal microbial populations - organisms that behave as parasites [1-3].

2.1 protozoans of human gastro-intestinal tract: its general characteristics

A wide array of protozoan organisms are frequently found in the human gastro-intestinal tract [20,21]. Actually, these organisms are not homogenous, or in other words, they cannot simply categorized in one group, because they come from different phylogenetic branches so that their morphologies and characteristics are also different [24]. Basically, their physiology and biochemistry properties are mostly customized to their parasitic properties which has been adapted to the local milieu where these parasites live [25]. They also exhibit different mechanisms of host invasion, some establish an infection through intracellular route (e.g., *Cryptosporidium* spp.) and some organisms developed a host specialization (e.g., *Entamoeba histolytica*), and to add complexity to invasion methods, many of them are also developed the ability to infect more than one host (e.g., *Giardia lamblia*) [26]. Von Huth et al [27] reported that intestinal protozoan infections directly shape fecal bacterial microbiota in children. These findings become an interesting subject for further exploration, for example regarding whether certain bacterial patterns are formed in certain protozoal infections, and whether the duration of parasitic infection then facilitates changes in the character of the microbiota from normal to opportunistic.

Clinical signs and symptoms of intestinal protozoan infections become apparent within one to three weeks post exposure [24,26]. Anatomically, few species of this intestinal protozoan actually caused gradual impairment to their predilection tissue; which if not handled properly can cause continuously derangement and ends in a permanent damage. But luckily, what happens more often is a mild infection characterized by a spectrum of symptoms such as: diarrhea, nausea, stomach cramps, gas, greasy stool (because fat absorption is being blocked), and possible dehydration.

Among the lists of protozoans capable conducting intestinal infections, the species *G. lamblia* could constitute an excellent sample to shed the light on some intermediary related to their initial reciprocity with the intestinal microflora and how they establish themselves and share the same milieu [28]. This flagellate parasite is commonly infect human and also a wide array of animal [29]. The array of clinical signs and symptoms differ from a very minimal lesion, e.g., mild and self-limiting illness, to a more obvious acute or even chronic-persistent diarrhea and also weight depletion, lethargy with malabsorption that can be remain for several months [28,29]. According to Kraft et al [30], intestinal protozoan infections are acquired via oral route, largely due to swallowing of cysts in adulterate drinking water. After entering the intestine, stage transformation took place, e.g., into the trophozoite stage, then this protozoans immediately adhere to the gut epithelium surface and start to colonize the duodenum and upper jejunum and in the end followed by the process of immediate replication, vegetatively. The consequences of Giardiasis may vary between individuals, from the condition of simply self-limiting to chronic, and also from the condition of asymptomatic to severe manifestations, with unspecific gastrointestinal complaints.

A condition of asymptomatic infection also widely reported, even though Kraft et al [30] proposed the possibility of 'false negative' due to minimum barrier that compromising activities of recent *G. Lamblia* isolates. The breakdown of intestinal barrier function is one of the proposed mechanism for intestinal protozoan pathogenesis. Analysis via the trans-epithelial electric resistances (TEER) or by indicators of epithelial permeability using labeled sugar compounds in in vitro cell culture systems, mouse models or human biopsies and epidemiological studies are type of studies conducted in order to support the previously mentioned mechanism of pathogenesis. Epithelial cell model infected with protozoan directly actually have the potency to be used as mimicking asymptomatic infection[30]. This perspective leads to the potency of using this model from just simply identification of *Giardia* virulence factors and shifted to exhibiting disease formation related to non-parasite factors. The underlying origin that determines variability in clinical sign and symptom are still not clear.

Several studies examined the process of invasion at the cellular level and how parasite products contributes to the tissue injury, locally. In the very early phase of invasion, the *Giardia* enzyme, e.g., cysteine proteinases, break the affected epithelial barrier, and which further arouses the host's inflammatory and immunological responses.³¹ Host with normal immune armamentarium can easily recognize the protozoans [32]; but when the immune failed, the protozoan inhabitation that parasitizing mucosal facet may arouse innate immune armamentarium, e.g., toll-like receptors (TLRs) [32,33]. T cells (particularly involving CD8+ cells), macrophages, neutrophils, and antibodies (e.g., IgM, IgG, and IgA) are major components of the acquired immune armamentarium necessary for the battle against giardiasis [34,35].

2.2 Interaction between protozoan infection Vs. intestinal microflora

Intestinal microflora portray an additional factor that may strongly prevent the protozoan parasite infections[1,2]. Unfortunately, the actual reciprocity between the normal intestinal microflora and protozoan parasites are still not revealed clearly, yet.

In animal model, e.g., mouse, normal gut microflora was shown to actively reduce the vulnerability to *Cryptosporidium parvum* invasion and changes in the microbiome of cryptosporidium-infected mice correlate to differences in its susceptibility and level of infection (e.g., mild-moderate-severe) [36]. In another animal study using goat, when *C. parvum* colonization took place, it reduced the affluence of butyrate-producing pathways in bacteria. Low grade of butyrate may stimulate mucosal inflammation and tissue restoration

[37]. This indicates that the intestinal inflammation induced by the protozoan *C. parvum* is related with the curtailment of butyrate-producing bacteria [38]. These findings strengthen our understanding about the existence and dominance of intestinal microflora that seems to be critical for the pathogenic pronouncement of several enteric protozoans such as *Blastocystis hominis*, *E. histolytica*, and different species of other enteric protozoan [39].

Human intestinal normal microflora populations are largely consist of not only bacteria, but also include viruses, fungi, protozoa and archaea, whose play an important role in the intestinal ecosystem. Humans that being colonized by *Blastocystis hominid* actually contain a more diverse bacterial microflora than individuals not carrying it [40]. The result suggests the beneficial contribution of harboring *Blastocystis* for the host [41]. There is contrasting microbiota profiles observed in children carrying either *Blastocystis* spp. or the commensal non-pathogenic amoebas *Entamoeba coli* or *Endolimax nana* with an expanded number and diversity-composition shifts in the bacterial microflora in children [42]. *Blastocystis hominis* that is more commonly isolated in industrialized community, which are otherwise mostly devoid of gut eukaryotes, on contrary among rural “traditional” society, which usually contain a greater diversity of intestinal eukaryotes (whether pathogenic or commensal) [43,44]. This interesting phenomenon must be carefully considered in order to study protozoa interactions in the gut ecosystem, based on their host’s location (rural vs urban).

Even et al [43] profiled the intestinal bacterial microflora of 134 healthy Cameroonian adults utilizing 16S rRNA gene amplicon sequencing data. The pattern of existence and occurrence *Entamoeba* and *Blastocystis* in a single individuals were decided using metagenomic shotgun data. When taking into consideration co-occurrence of both protozoa simultaneously, *Blastocystis* was always related with both a higher richness and a higher likeness of the gut bacterial microbiota, while on contrary *Entamoeba* was associated only with a higher abundance. The existence of these parasitic protozoa affect the bacterial microflora diversity [9,45]. This interaction clearly contribute to the well being of their host [12,19,23]. The abundance of several customary taxa (e.g, *Coprococcus*, *Ruminococcaceae*, and *Butyrivibrio*) diversified due to *Blastocystis* colonization, but only a single *Bacteroides* amplicon sequence strain was found profusely between *Entamoeba* (-) and *Entamoeba* (+) samples. Based on the result of study conducted by Even et al [43], *Blastocystis* and *Entamoeba* have definite interaction with gut bacteria each in its own way.

2.3. Hypotheses regarding protozoan pathogenic stimulation by the resident normal microflora

Normal microflora evolves complex mechanisms to restrict pathogen growth, by way of (1) Preventing of attachment [46], (2) Competitive metabolic interactions [47], (3), Niche exclusion [48], (4) Nutrient competition [49] and (5) Induction of host immune response [50], which are collectively termed colonization resistance [51]. On the other hand, pathogens have also developed counterstrategies to expand their population and enhance their virulence to cope with the gut microbiota colonization resistance and cause infection [51,52].

One hypothesis is due to axenization of the parasites. Axenization means the process of isolating a particular organism from all others; in the context of purifying and making pure culture, axenization of certain organism allows concentrated groups to be studied and perhaps countable. In this scenario, the superficial saccharide ligands which located on the protozoan outermost membrane are changed by the attendance of intracellular bacterial symbionts. so the phenomenon seen in axenic protozoa that was being cured of their endosymbionts, resulted in a clear and viable decline in protozoan’s adhesive ability and or

invasive properties. Also in the case of *Giardia*, a study conducted using murine model revealed the ultrastructural scrutiny of *G. muris* disclosed endosymbiotic microbes which could be related to disparity in the parasite's stage pathogenicity, rate of infectivity, metabolism, antigenic surface profiles, and even determine host specificity. Based on TEM examination, the occurrence of *Giardia* trophozoites harboring superficial bacterial endosymbionts was also confirmed [53]. Only trophozoites which contain endosymbionts were destroyed when in close vicinity of the activated Paneth cells, endorsing the host's preservative role of the bacterial endosymbionts within *Giardia* trophozoites [54]. Those previously mentioned facts further supporting the idea that intestinal microflora may directly and indirectly affect the pathogenesis of giardiasis.

The second hypothesis comes from the result of a study conducted by Mirelman et al [55] using non-pathogenic *E. histolytica* strain. These researchers found out that axenisation of the host that took place at the intestinal level can be involved in the virulence expression of certain intestinal protozoan parasites [56]. Interactions of minor pathogenic amoebae with a variety of Gram-negative bacteria that occupy certain milieu of the intestine, mainly *E. coli* strains, may be in charge of the increase in amoebic virulence [57]. Galván-Moroyoqui et al. [58] demonstrated that phagocytosis of enteropathogenic bacteria strains (e.g., *E. coli* and *Shigella dysenteriae*) in vitro and co-cultured them together with *E. histolytica* and *E. dispar*; this mixture turns to multiply the cytopathic effect of *E. histolytica* and make them more virulent by way of increasing expression of Gal/GalNAc lectin on the amoebic surface and the cysteine proteinase activity, but for *E. dispar* continued avirulent.

In case of *G. lamblia*, several previous studies have proved that the normal intestinal microflora may arouse the pathogenic expression of this pathogen, but fortunately not the multiplication effort of parasites [59]. In a gnotobiotic animal model, Torres et al. (2000) apportioned evidence that the microorganism responsible for part of the invigoration of *G. lamblia* pathogenicity are exist dominantly in the duodenal [60]. Facultative and strictly anaerobic bacterial of the duodenal normal microflora were acquired from biopsy of several individuals with clinical diagnosis of giardiasis. These micro-organisms further challenged for their ability to arouse *G. lamblia* pathogenicity in animal model (gnotoxenic mice). By quantifying the number of cysts in faecal material and of trophozoites isolation from the small intestine was also accomplished. This approach aims to carefully analyse the protozoan multiplication ability in the different groups of mice. The result revealed that (1) Germ-free mice did not undergo any pathological alterations throughout the course of experimental *Giardia* infection; (2) Infected gnotoxenic mice exhibited intermediate pathological changes between the group of germ-free and the infected conventional mice group accustomed as controls; (3) No histo-pathological appearance were obtained in the non-infected gnotoxenic or conventional group of animals. As shown also for other intestinal pathogenic protozoans, bacterial sub-population from the intestinal microflora display stimulatory factors for *Giardia* pathogenicity only but must be kept in mind not for protozoan multiplication; because the number of faecal cysts remained similar among the three different groups of mice during the course of experimental infection [60].

The need to reveal the role of parasitome and the metabolome of intestinal normal microflora during chronic-persistent parasitic infection and their relationship with the host's immunoregulatory mechanisms is urgent, because better understanding regarding this topic will help clinicians to improve their clinical management approach while taking care of their patients.

These findings strengthen our understanding about the role of resident normal microflora of the intestine that can stimulate the pathogenicity of some intestinal protozoan. Beside

normal microflora, probiotics have the potency to prevent evolution of some protozoan parasite; which will be discuss in the following section [61].

2.4 The potency of Probiotics against protozoan parasites

Probiotics inhibits the advancement of certain intestinal pathogens [61,62]. Probiotics also effective and efficient in the supportive management of gastrointestinal disorders [61,62], infection based respiratory disease [63], and allergic symptoms [64], and also can kill or inhibit or even kills strain-specific pathogens [65] through several mechanisms, namely (1) Competition [66], (2) Molecule secretion [67], and/or (3) Immune induction [62].

Configuration of the intestinal flora was likely involved in the highly variable manifestations in giardiasis in both humans and animals [68]. Pérez et al. [69] analysed the effect of several different probiotic bacteria (six *Lactobacillus acidophilus* strains, and *Lactobacillus johnsonii* La1) on *G. lamblia* strain, in vitro. The result showed that only *L. johnsonii* La1 clearly stopped the multiplication of *Giardia* trophozoites. Data from in vivo experiment support the previously mentioned fact where protection against parasite-induced mucosal damage and a sufficient cellular feedback to *Giardia* antigens was stimulated in spleen cells from La1-treated animals, bring about a refinement of infection [70].

Furthermore due to an in vivo study using animal model, the addition of *L. casei* MTCC 1423 strain as well as *E. faecium* SF68 were both adequate in annihilating *Giardia* infection in probiotic-fed mice by reducing or avoiding attachment of *Giardia* trophozoites-mucosal surface and arousing an early humoral response [71].

Previously, the potency of several *Lactobacillus* species/strains to intercept and even to cure murine *Giardia* infection has also been reported [72]. In general, all showing the positive effect of the addition of *L. casei* to *Giardia lamblia* infected BALB/c mice; most studies corroborate the contribution of adding probiotics to susceptible host in order to minimize the length and severity of infection through the direct action of probiotics organisms on convalescence of the intestine, morphologically and physiologically [73]. Further study need to be conducted regarding the potency and the possibility of probiotics for their therapeutic use for humans.

3. CONCLUSION

Human as host, the resident intestinal microflora and the protozoan parasites are connected and interfere each other, and as the result build in a complex ecosystem where alterations in one member of these components may govern a counter response in the remaining ones. Normal microflora have the ability to prevent protozoan infection, and the addition of certain probiotics helps the host recover faster and better.

REFERENCES

1. Drew GC, Stevens EJ, King KC. Microbial evolution and transitions along the parasite–mutualist continuum. *Nat Rev Microbiol* 2021;19, 623–38. <https://doi.org/10.1038/s41579-021-00550-7>
2. Khan I, Bai Y, Zha L, et al. Mechanism of the Gut Microbiota Colonization Resistance and Enteric Pathogen Infection. *Front Cell Infect Microbiol*. 2021;11:716299. <https://doi.org/10.3389/fcimb.2021.716299>
3. Braga RM, Dourado MN, Araújo WL. Microbial interactions: ecology in a molecular perspective. *Braz J Microbiol*. 2016 Dec;47 Suppl 1(Suppl 1):86-98. <https://doi.org/10.1016/j.bjm.2016.10.005>
4. Deo PN, Deshmukh R. Oral microbiome: Unveiling the fundamentals. *J Oral Maxillofac Pathol*. 2019;23(1):122-128. https://doi.org/10.4103/jomfp.JOMFP_304_18
5. Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. *PeerJ*. 2019;7:e7502. <https://doi.org/10.7717/peerj.7502>
6. Coyte KZ, Rakoff-Nahoum S. Understanding Competition and Cooperation within the Mammalian Gut Microbiome. *Curr Biol*. 2019;29(11):R538-R544. <https://doi.org/10.1016/j.cub.2019.04.017>
7. Chiu L, Bazin T, Truchetet ME, Schaefferbeke T, Delhaes L, Pradeu T. Protective Microbiota: From Localized to Long-Reaching Co-Immunity. *Front Immunol*. 2017;8:1678. <https://doi.org/10.3389/fimmu.2017.01678>
8. Bauer MA, Kainz K, Carmona-Gutierrez D, Madeo F. Microbial wars: Competition in ecological niches and within the microbiome. *Microb Cell*. 2018;5(5):215-219. <https://doi.org/10.15698/mic2018.05.628>
9. Sunarti LS. Microbial Normal Flora: Its Existence And Their Contribution To Homeostasis. *Journal of Advances in Microbiology*, 2022; 22(9):1-15 <https://doi.org/10.9734/JAMB/2022/v22i930483>
10. Cahana I, Iraqi FA. Impact of host genetics on gut microbiome: Take-home lessons from human and mouse studies. *Animal Model Exp Med*. 2020;3(3):229-36. <https://doi.org/10.1002/ame2.12134>
11. Kaan AMM, Kahharova D, Zaura E. Acquisition and establishment of the oral microbiota. *Periodontol* 2000. 2021;86(1):123-141. <https://doi.org/10.1111/prd.12366>
12. Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. *Expert Rev Anti Infect Ther*. 2010;8(4):435-54. <https://doi.org/10.1586/eri.10.14>

13. Rutsch A, Kantsjö JB, Ronchi F. The Gut-Brain Axis: How Microbiota and Host Inflammation Influence Brain Physiology and Pathology. *Front Immunol.* 2020;11:604179. [https://doi.org/ 10.3389/fimmu.2020.604179](https://doi.org/10.3389/fimmu.2020.604179)
14. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol.* 2015;21(29):8787-8803. <https://doi.org/10.3748/wjg.v21.i29.8787>
15. Das P, Babaei P, Nielsen J. Metagenomic analysis of microbe-mediated vitamin metabolism in the human gut microbiome. *BMC Genomics.* 2019;20(1):208. [https://doi.org/ 10.1186/s12864-019-5591-7](https://doi.org/10.1186/s12864-019-5591-7).
16. Soto-Martin EC, Warnke I, Farquharson FM, Christodoulou M, Horgan GW, Derrien M, et al. Vitamin Biosynthesis by Human Gut Butyrate-Producing Bacteria and Cross-Feeding in Synthetic Microbial Communities. *mBio,* 2020;11. [https://doi.org/ 10.1128/mBio.00886-20](https://doi.org/10.1128/mBio.00886-20)
17. Koppel N, Maini Rekdal V, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. *Science.* 2017 Jun 23;356(6344):eaag2770. [https://doi.org/ 10.1126/science.aag2770](https://doi.org/10.1126/science.aag2770).
18. Abdelsalam NA, Ramadan AT, ElRakaiby MT, Aziz RK. Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics. *Front Pharmacol.* 2020;11:390. <https://doi.org/10.3389/fphar.2020.00390>
19. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res,*2020; 30: 492–506. <https://doi.org/10.1038/s41422-020-0332-7>
20. Naveed A, Abdullah S. Impact of parasitic infection on human gut ecology and immune regulations. *transl med commun* [2021; 6: 11. <https://doi.org/10.1186/s41231-021-00091-4>
21. Wolday D, Tasew G, Amogne W. Interrogating the Impact of Intestinal Parasite-Microbiome on Pathogenesis of COVID-19 in Sub-Saharan Africa. *Front Microbiol.* 2021;12:614522. <https://doi.org/10.3389/fmicb.2021.614522>
22. Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. *Microbiome* 2019;7: 91. <https://doi.org/10.1186/s40168-019-0704-8>
23. Agus A, Planchais J, Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. *Cell Host Microbe.* 2018 Jun 13;23(6):716-724. doi: 10.1016/j.chom.2018.05.003. PMID: 29902437.
24. Vaisusuk, K, Saijuntha W. Intestinal Protozoa: Their Role as Human Pathogens and Zoonoses. In: Petney, T.N., Saijuntha, W., Mehlhorn, H. (eds) *Biodiversity of Southeast Asian Parasites and Vectors causing Human Disease.* Parasitology Research Monographs, 2021; 14. Springer, Cham. https://doi.org/10.1007/978-3-030-71161-0_3
25. Lively CM, Dybdahl MF. Parasite adaptation to locally common host genotypes. *Nature.* 2000;405(6787):679-81. [https://doi.org/ 10.1038/35015069](https://doi.org/10.1038/35015069).

26. Di Genova BM, Tonelli RR. Infection Strategies of Intestinal Parasite Pathogens and Host Cell Responses. *Front Microbiol.* 2016;7:256. <https://doi.org/10.3389/fmicb.2016.00256>
27. von Huth S, Thingholm LB, Kofoed PE. Intestinal protozoan infections shape fecal bacterial microbiota in children from Guinea-Bissau. *PLoS Negl Trop Dis.* 2021;15(3):e0009232. <https://doi.org/10.1371/journal.pntd.0009232>
28. Fekete E, Allain T, Siddiq A, Sosnowski O, Buret AG. Giardia spp. and the Gut Microbiota: Dangerous Liaisons. *Front Microbiol.* 2021;11:618106. <https://doi.org/10.3389/fmicb.2020.618106>
29. Feng Y, Xiao L. Zoonotic potential and molecular epidemiology of Giardia species and giardiasis. *Clin Microbiol Rev.* 2011;24(1):110-140. <https://doi.org/10.1128/CMR.00033-10>
30. Kraft MR, Klotz C, Bücken R, Schulzke JD, Aebischer T. Giardia's Epithelial Cell Interaction In Vitro: Mimicking Asymptomatic Infection?. *Front Cell Infect Microbiol.* 2017;7:421. <https://doi.org/10.3389/fcimb.2017.00421>
31. Liu J, Ma'ayeh S, Peirasmaki D, Lundström-Stadelmann B, Hellman L, Svärd SG. Secreted Giardia intestinalis cysteine proteases disrupt intestinal epithelial cell junctional complexes and degrade chemokines. *Virulence.* 2018;9(1):879-94. <https://doi.org/10.1080/21505594.2018.1451284>
32. Humayun M, Ayuso JM, Park KY, Martorelli Di Genova B, Skala MC, Kerr SC, Knoll LJ, Beebe DJ. Innate immune cell response to host-parasite interaction in a human intestinal tissue microphysiological system. *Sci Adv.* 2022;8(18):eabm8012. <https://doi.org/10.1126/sciadv.abm8012>
33. Solaymani-Mohammadi S. Mucosal Defense Against Giardia at the Intestinal Epithelial Cell Interface. *Front Immunol.* 2022;13:817468. <https://doi.org/10.3389/fimmu.2022.817468>
34. Zhao P, Cao L, Wang X. Extracellular vesicles secreted by Giardia duodenalis regulate host cell innate immunity via TLR2 and NLRP3 inflammasome signaling pathways. *PLoS Negl Trop Dis.* 2021;15(4):e0009304. <https://doi.org/10.1371/journal.pntd.0009304>
35. Ihara S, Miyamoto Y, Le CHY. Conserved metabolic enzymes as vaccine antigens for giardiasis. *PLoS Negl Trop Dis.* 2022;16(4):e0010323. <https://doi.org/10.1371/journal.pntd.0010323>
36. Charania R, Wade BE, McNair NN, Mead JR. Changes in the Microbiome of Cryptosporidium-Infected Mice Correlate to Differences in Susceptibility and Infection Levels. *Microorganisms.* 2020;8(6):879. <https://doi.org/10.3390/microorganisms8060879>
37. Mammeri M, Obregón DA, Chevillot A, Polack B, Julien C, Pollet T, et al. Cryptosporidium parvum Infection Depletes Butyrate Producer Bacteria in Goat Kid Microbiome. *Front Microbiol.* <https://doi.org/10.3389/fmicb.2020.548737>. PMID: 33178145; PMCID: PMC7596689.

38. Chen J, Vitetta L. The Role of Butyrate in Attenuating Pathobiont-Induced Hyperinflammation. *Immune Netw.* 2020;20(2):e15. <https://doi.org/10.4110/in.2020.20.e15>
39. Villa, T.G., Sánchez-Pérez, A., Viñas, M. (2016). The Biological Fight Against Pathogenic Bacteria and Protozoa. In: Villa, T., Vinas, M. (eds) *New Weapons to Control Bacterial Growth*. Springer, Cham. https://doi.org/10.1007/978-3-319-28368-5_19
40. Castañeda S, Muñoz M, Villamizar X, et al. Microbiota characterization in Blastocystis-colonized and Blastocystis-free school-age children from Colombia. *Parasit Vectors.* 2020;13(1):521. <https://doi.org/10.1186/s13071-020-04392-9>
41. Deng L, Wojciech L, Gascoigne NRJ, Peng G, Tan KSW. New insights into the interactions between Blastocystis, the gut microbiota, and host immunity. *PLoS Pathog.* 2021;17(2):e1009253. <https://doi.org/10.1371/journal.ppat.1009253>
42. Alzate JF, Toro-Londoño M, Cabarcas F, Garcia-Montoya G, Galvan-Diaz A. Contrasting microbiota profiles observed in children carrying either Blastocystis spp. or the commensal amoebas Entamoeba coli or Endolimax nana. *Sci Rep.* 2020;10(1):15354. <https://doi.org/10.1038/s41598-020-72286-y>
43. Even G, Lokmer A, Rodrigues J, et al. Changes in the Human Gut Microbiota Associated With Colonization by Blastocystis sp. and Entamoeba spp. in Non-Industrialized Populations. *Front Cell Infect Microbiol.* 2021;11:533528. <https://doi.org/10.3389/fcimb.2021.533528>
44. Parfrey LW, Walters WA, Lauber CL. Communities of microbial eukaryotes in the mammalian gut within the context of environmental eukaryotic diversity. *Front Microbiol.* 2014;5:298. <https://doi.org/10.3389/fmicb.2014.00298>
45. Chabé M, Lokmer A, Ségurel L. Gut Protozoa: Friends or Foes of the Human Gut Microbiota? *Trends Parasitol.* 2017;33(12):925-34. <https://doi.org/10.1016/j.pt.2017.08.005>
46. Leung JM, Graham AL, Knowles SCL. Parasite-Microbiota Interactions With the Vertebrate Gut: Synthesis Through an Ecological Lens. *Front Microbiol.* 2018;9:843. <https://doi.org/10.3389/fmicb.2018.00843>
47. Dai D, Wang T, Wu S, Gao NL, Chen WH. Metabolic Dependencies Underlie Interaction Patterns of Gut Microbiota During Enteropathogenesis. *Front Microbiol.* 2019;10:1205. <https://doi.org/10.3389/fmicb.2019.01205>
48. Dodge R, Jones E, Zhu H, Obadia B, Martinez D, Wang C, et al. (2021). A gut commensal niche regulates stable association of a multispecies microbiota. <https://doi.org/10.1101/2021.09.30.462663>.
49. Estrela S, Sanchez-Gorostiaga A, Vila JC, Sanchez A. Nutrient dominance governs the assembly of microbial communities in mixed nutrient environments. *Elife.* 2021;10:e65948. <https://doi.org/10.7554/eLife.65948>

50. Lazar V, Ditu LM, Pircalabioru GG, et al. Aspects of Gut Microbiota and Immune System Interactions in Infectious Diseases, Immunopathology, and Cancer. *Front Immunol.* 2018;9:1830. <https://doi.org/10.3389/fimmu.2018.01830>
51. Sorbara MT, Pamer EG. Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. *Mucosal Immunol.* 2019;12(1):1-9. <https://doi.org/10.1038/s41385-018-0053-0>. Epub 2018 Jul 9. Erratum in: *Mucosal Immunol.* 2019 May;12(3):840.
52. Kantele A, Kuenzli E, Dunn SJ, Dance DAB, Newton PN, Davong V, et al. Dynamics of intestinal multidrug-resistant bacteria colonisation contracted by visitors to a high-endemic setting: a prospective, daily, real-time sampling study. *Lancet Microbe.* 2021 ;2(4):e151-e158. [https://doi.org/10.1016/S2666-5247\(20\)30224-X](https://doi.org/10.1016/S2666-5247(20)30224-X).
53. El-Shewy KA, Eid RA. In vivo killing of *Giardia* trophozoites harbouring bacterial endosymbionts by intestinal Paneth cells: an ultrastructural study. *Parasitology.* 2005;130(Pt 3):269-74. <https://doi.org/10.1017/s0031182004006547>.
54. Pérez PF, Minnaard J, Rouvet M, et al. Inhibition of *Giardia intestinalis* by extracellular factors from *Lactobacilli*: an in vitro study. *Appl Environ Microbiol.* 2001;67(11):5037-5042. <https://doi.org/10.1128/AEM.67.11.5037-5042.2001>
55. Mirelman D, Bracha R, Wexler A, Chayen A. Changes in isoenzyme patterns of a cloned culture of nonpathogenic *Entamoeba histolytica* during axenization. *Infect Immun.* 1986;54(3):827-832. <https://doi.org/10.1128/iai.54.3.827-832.1986>
56. Shi Y, Queller DC, Tian Y. The Ecology and Evolution of Amoeba-Bacterium Interactions. *Appl Environ Microbiol.* 2021;87(2):e01866-20. <https://doi.org/10.1128/AEM.01866-20>
57. Fernández-López LA, Gil-Becerril K, Galindo-Gómez S. *Entamoeba histolytica* Interaction with Enteropathogenic *Escherichia coli* Increases Parasite Virulence and Inflammation in Amebiasis. *Infect Immun.* 2019;87(12):e00279-19. <https://doi.org/10.1128/IAI.00279-19>
58. Galván-Moroyoqui JM, Del Carmen Domínguez-Robles M, Franco E, Meza I. The interplay between *Entamoeba* and enteropathogenic bacteria modulates epithelial cell damage. *PLoS Negl Trop Dis.* 2008;2(7):e266. <https://doi.org/10.1371/journal.pntd.0000266>
59. Bartelt LA, Sartor RB. Advances in understanding *Giardia*: determinants and mechanisms of chronic sequelae. *F1000Prime Rep.* 2015;7:62. <https://doi.org/10.12703/P7-62>.
60. Torres MF, Uetanabaro APT, Costa AF, Alves CA, Farias LM, Bambirra EA, et al. Influence of bacteria from the duodenal microbiota of patients with symptomatic giardiasis on the pathogenicity of *Giardia duodenalis* in gnotoxenic mice. *J Med Microbiol.* 2000;49(3):209-215. <https://doi.org/10.1099/0022-1317-49-3-209>.
61. Al-Megrin WA, Mohamed SH, Saleh MM, Yehia HM. Preventive role of probiotic bacteria against gastrointestinal diseases in mice caused by *Giardia lamblia*. *Biosci Rep.* 2021; 41 (2): BSR20204114. <https://doi.org/10.1042/BSR20204114>

62. Raheem A, Liang L, Zhang G, Cui S. Modulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation. *Front Immunol.* 2021;12:616713. <https://doi.org/10.3389/fimmu.2021.616713>
63. Mortaz E, Adcock IM, Folkerts G, Barnes PJ, Paul Vos A, Garssen J. Probiotics in the management of lung diseases. *Mediators Inflamm.* 2013;2013:751068. <https://doi.org/10.1155/2013/751068>
64. Michail S. The role of probiotics in allergic diseases. *Allergy Asthma Clin Immunol.* 2009;5(1):5. <https://doi.org/10.1186/1710-1492-5-5>
65. Campana R, van Hemert S, Baffone W. Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. *Gut Pathog.* 2017;9:12. <https://doi.org/10.1186/s13099-017-0162-4>
66. Knipe H, Temperton B, Lange A, Bass D, Tyler CR. Probiotics and competitive exclusion of pathogens in shrimp aquaculture. *Rev. Aquacult.* 2021; 13: 324-52. <https://doi.org/10.1111/raq.12477>
67. Indira M, Venkateswarulu TC, Abraham Peele K, Nazneen Bobby M, Krupanidhi S. Bioactive molecules of probiotic bacteria and their mechanism of action: a review. *3 Biotech.* 2019;9(8):306. <https://doi.org/10.1007/s13205-019-1841-2>
68. Singer SM, Nash TE. The Role of Normal Flora in *Giardia lamblia* Infections in Mice, *The Journal of Infectious Diseases,* 2000;181(4):1510–2. <https://doi.org/10.1086/315409>
69. Pérez PF, Minnaard J, Rouvet M. Inhibition of *Giardia intestinalis* by extracellular factors from *Lactobacilli*: an in vitro study. *Appl Environ Microbiol.* 2001;67(11):5037-5042. <https://doi.org/10.1128/AEM.67.11.5037-5042.2001>
70. Humen MA, De Antoni GL, Benyacoub J. *Lactobacillus johnsonii* La1 antagonizes *Giardia intestinalis* in vivo. *Infect Immun.* 2005;73(2):1265-1269. <https://doi.org/10.1128/IAI.73.2.1265-1269.2005>
71. Travers MA, Florent I, Kohl L, Grellier P. Probiotics for the control of parasites: an overview. *J Parasitol Res.* 2011;2011:610769. <https://doi.org/10.1155/2011/610769>
72. Shukla G, Devi P, Sehgal R. Effect of *Lactobacillus casei* as a probiotic on modulation of giardiasis. *Dig Dis Sci.* 2008;53(10):2671-9. <https://doi.org/10.1007/s10620-007-0197-3>.
73. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JNV, Suttrop MJ, et al. Safety of Probiotics to Reduce Risk and Prevent or Treat Disease. Evidence Report/Technology Assessment No. 200. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290-2007-10062-I.) AHRQ Publication No. 11-E007. Rockville, MD: Agency for Healthcare Research and Quality. April 2011. Available at:www.ahrq.gov/clinic/tp/probiotictp.htm.